Your Chief AI Officer · Monday, November 16, 2026 · Act today
Wolters Kluwer to acquire AgileMD for up to $100 million
Reported2 sourcesFor patients and employees
Wolters Kluwer Health will acquire AI clinical decision support platform AgileMD for up to $100 million, reported by HIT Consultant and HIStalk. AgileMD's Pathways platform puts institution-specific guidelines into EHR charting and order entry, and it brings FDA-cleared eCART surveillance; the deal aims to embed UpToDate Expert AI inside EHR workflows.
Wolters Kluwer Health has signed a definitive agreement to acquire San Francisco-based AgileMD for up to $100 million, made up of $40 million in upfront cash and up to $60 million in performance-based deferred consideration, according to HIT Consultant. HIStalk also reported the deal. AgileMD brings two products. Pathways puts institution-specific clinical guidelines inside the clinician's native charting and order-entry environment. eCART is an FDA 510(k)-cleared real-time surveillance engine that analyzes vital signs, lab results and demographic data in the EHR to flag inpatient deterioration and trigger escalation.
The strategic logic is distribution. Wolters Kluwer says UpToDate Expert AI has been adopted by more than 2,700 U.S. hospitals and health systems since its September 2025 launch, which it puts at over 95 percent of its U.S. Enterprise Edition customers, per HIT Consultant. Senior Vice President Yaw Fellin described AgileMD as an enabler for "true UpToDate ubiquity," meaning expansion into embedded workflows, local guidelines and new digital health applications. For most hospitals, the reference tool clinicians already search is about to become a vendor pushing guidance into order entry and bedside alerts.
The economics show what Wolters Kluwer is betting. Based on AgileMD's projected $7 million in year-end 2026 annual recurring revenue, the upfront payment is roughly 5.7 times revenue and the full price implies 14.3 times, contingent on commercial execution. The company expects return on invested capital at or above its 8 percent after-tax cost of capital within three to five years, with immaterial near-term earnings impact, per the same report. Deferred consideration tied to performance means the seller is rewarded for growth, which usually means bundling and upsell to an existing customer base.
What the evidence does not yet show: there are no independent outcome data on the combined product. eCART's design goals of predicting deterioration and reducing mortality are the company's description, and FDA clearance is not the same as proof of results in your patient population. Embedded alerts also carry an alert-fatigue risk for nurses and physicians that only local validation can measure.
The move: before the deal closes, ask your UpToDate and AgileMD account teams how pricing, contract terms and EHR integration will change, whether Pathways and eCART will be bundled with UpToDate renewals, and what validation data they will share. CMOs and CIOs should agree in advance on who governs locally authored guidelines once they live inside a vendor platform, and what performance evidence an embedded surveillance alert must meet before it reaches the bedside.
Do this week. Ask your UpToDate and AgileMD account teams how pricing, contracts and EHR integration will change after the deal closes.
Run this
The prompt to act on this item, for your own model.
Paste it into Claude, ChatGPT or Copilot and fill the bracketed slots with your own numbers. The output is a draft for your team to check, built only from the sources on this page. Never paste patient data. How these prompts are written.
You are an advisor to the CIO, CTO and Chief Medical Officer of [your organization], preparing us for vendor conversations about a clinical decision support acquisition. Context. HIT Consultant and HIStalk report that Wolters Kluwer Health has signed a definitive agreement to acquire AgileMD for up to $100 million: $40 million in upfront cash and up to $60 million in performance-based deferred consideration. AgileMD's Pathways puts institution-specific guidelines inside EHR charting and order entry. eCART is an FDA 510(k)-cleared surveillance engine that analyzes vital signs, lab results and demographic data to flag inpatient deterioration. Wolters Kluwer says the deal embeds UpToDate Expert AI and eCART inside EHR workflows, and says UpToDate Expert AI is in more than 2,700 U.S. hospitals and health systems since its September 2025 launch. There is no independent evidence yet on outcomes from the combined product, and FDA clearance is not proof of results in our population. Task. Draft a vendor question list for our UpToDate and AgileMD account teams, to use before the deal closes. Group the questions under: pricing and contract terms, bundling with UpToDate renewals, integration with [your EHR], validation data they will share, alert fatigue, and governance of our locally authored guidelines. Add a short internal note naming who should own guideline governance and what evidence an embedded alert must meet before reaching the bedside. Our details: UpToDate renewal date [your renewal date], current annual spend [your current UpToDate contract value], current AgileMD use [none, Pathways, eCART, or both], guideline governance today [your committee or owner]. Guardrails. Use only the facts above and the details I fill in. Cite HIT Consultant and HIStalk by name. Flag anything uncertain or that we must verify with the vendor. Do not request or include patient data. Nothing here is medical advice. Label the output as a draft for our team to check.
- The claim.
- Wolters Kluwer says the deal embeds UpToDate Expert AI and eCART surveillance inside EHR workflows.
- The evidence.
- No independent evidence yet on outcomes from the combined product.
By seat
For the Chief AI Officer. Update the vendor map for clinical decision support and note consolidation risk in renewals.
For the Chief Medical Officer and physicians. Review which institutional pathways you maintain and whether they would move into the combined product.
Checked before publishing. 2 independent outlets. 1 figure matched to the source text.
Sources
Drafted by Lumen from the sources above, scored by a second pass on six criteria, then checked by rule against those sources (every figure, two independent outlets or a primary source) and published only when it passes. A person can pull any item, and corrections are published here. Apolitical, always. Nothing here is medical advice. How Your Chief AI Officer is made.